Premium
Kinetic of regulatory CD25 high and activated CD134 + (OX40) T lymphocytes during acute and chronic graft‐ versus ‐host disease after allogeneic bone marrow transplantation
Author(s) -
Sanchez Joaquin,
Casaño Javier,
Alvarez Miguel A.,
RomanGomez Jose,
Martin Carmen,
Martinez Francisco,
Gomez Pedro,
Serrano Josefina,
Herrera Concepcion,
Torres Antonio
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.05108.x
Subject(s) - il 2 receptor , graft versus host disease , medicine , transplantation , immunology , ex vivo , population , bone marrow , in vivo , t cell , biology , immune system , microbiology and biotechnology , environmental health
Summary Graft‐ versus ‐host disease (GVHD) is still a major complication after allogeneic stem cell transplantation. In murine models, freshly isolated or ex vivo expanded CD4 + CD25 high regulatory T cells (Treg) are able to ameliorate GVHD while maintaining graft‐ versus ‐leukaemia reactions. However, in the human setting, prospective studies of this population and its interaction with activated non‐regulatory CD134 + (OX40) lymphocytes during post‐transplant follow‐up are lacking. In this study, we prospectively quantified CD4 + CD25 high and activated CD134 + lymphocytes in 119 peripheral blood samples from 35 consecutive patients who underwent allogeneic bone marrow transplantation (BMT). Fifty‐five samples obtained less than 100 d after allogeneic BMT, were not statistically different regarding CD4 + CD25 high Treg or CD134 + lymphocytes compared with those obtained from patients with ( n = 35) or without ( n = 20) acute GVHD. Chronic GVHD was associated with a small, but not statistically significant, increase in the number of Treg (9·9 vs. 6·7 × 10 6 /L). However, the CD134/CD25 high ratio was significantly higher during chronic GVHD (cGHVD) when compared with either patients without cGVHD (67·7 ± 40·3 vs. 4·0 ± 0·9, P < 0·01) or cGVHD after treatment (67·7 ± 40·3 vs. 3·7 ± 0·8, P < 0·01). Our findings suggest that the suppressive activity of CD4 + CD25 high Treg could be abrogated in vivo during cGVHD by CD134 expression in a much higher number of activated donor T lymphocytes. In addition to CD4 + CD25 high ex vivo expansion protocols, OX40 blocking might be crucial to optimize the use of Treg to prevent GVHD.